Highlights Newsletter 4
This newsletter presents you the following key sessions:
1. Video-interview with Professor Dominique Bron about unmet needs in the treatment of Hodgkin lymphoma patients
2. Pivotal ZUMA-1 study: axicabtagene ciloleucel (axi-cel) improves outcome for patients with refractory aggressive
non-Hodgkin lymphoma
3. Early metabolic response determination by FDG-PET allows substantial reduction of chemotherapy and its toxicity
in patients with advanced stage Hodgkin lymphoma
4. Addition of daratumumab to Rd or Vd improves treatment outcomes for both the standard-risk and high-risk
patients with relapsed or refractory multiple myeloma
5. Patients with relapsed/refractory B-cell malignancies treated with cerdulatinib, a dual Syk-JAK inhibitor, have
rapid tumor responses